Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data. Gastrointestinal diseases are one of the Japanese ...

Studio Pierrot has unveiled the first teaser trailer and key visual for the final part of the Bleach anime, Thousand-Year Blood War (TYBW) Cour 4, confirming its release in July 2026. This last ...

S&P 500, Nasdaq close at records on tech lift, Iran peace talk hopes The S&P 500 and Nasdaq closed at record highs on Friday, bolstered by optimism for possible negotiations between the U.S. and Iran ...

An exercise-driven course on Advanced Python Programming that was battle-tested several hundred times on the corporate-training circuit for more than a decade. Written by David Beazley, author of the ...

It’s always fun to see a seconde/seconde/ take on a popular watch. With the many whimsical releases Romaric André created while collaborating with brands, you sometimes wonder whether he is ever short ...

Abstract: Python has become the programming language of choice for research and industry projects related to data science, machine learning, and deep learning. Since optimization is an inherent part ...

COUR is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of COUR shares has increased $0.10 since the market last closed. This is a 1.88 ...

The Python extension will automatically install the following extensions by default to provide the best Python development experience in VS Code: If you set this setting to true, you will manually opt ...

The latest Citizen Tsuyosa model sees it gain an artistic touch. That comes courtesy of renowned horological artist, seconde/seconde/. One of the most iconic watch releases in recent years is the ...

“Being smaller never stopped minutes from slicing hours into pieces,” reads the caseback of the new Tsuyosa x seconde/seconde/. It may sound like an ancient Japanese proverb, but it was written by the ...

Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company ...